View Older Stories View More Recent Stories
-
MacroGenics Announces Pricing of Public Offering of Common Stock
-
RedHill Biopharma (RDHL) Plans ADS Offering
-
RedHill Biopharma Announces Proposed Public Offering of Its American Depository Shares
-
Roth Positive on Cytokinetics (CYTK) Following Phase III VITALITY-ALS Initiation
-
Roth Positive on Ballard Power's (BLDP) Protonex Acquisition; Offers Commentary
-
Vermillion (VRML) Prices 8.35M Common Stock Offering at $1.96/Share
-
Vermillion, Inc. Prices $16.4 Million Public Offering of Common Stock
-
Tonix Pharmaceuticals (TNXP) Prices 2.33M Common Stock Offering at $7.50/Share
-
Tonix Pharmaceuticals Prices Underwritten Public Offering of Common Stock
-
Cempra (CEMP) Added to Focus List at Roth Capital
-
DepoMed (DEPO) PT Raised to $33 at Roth Capital on Expected Higher Bid
-
Roth Capital Raises Price Target on PriceSmart (PSMT) Following 3Q15 Results
-
Roth Capital Maintains Neutral on ZAGG, Inc. (ZAGG) Ahead of 2Q15 Results
-
Vermillion (VRML) Plans Public Offering of Common Stock
-
Tonix Pharmaceuticals (TNXP) Plans Common Stock Offering
-
Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Vermillion, Inc. Announces Proposed Public Offering of Common Stock
-
Ohr Pharmaceutical (OHRP) Bullish Stance Reiterated at Roth Capital Following Encouraging Data
-
Roth Capital Raises Price Target on NeoGenomics (NEO) Ahead of Potential Reimbursement Changes
-
Roth Capital Raises Price Target on Increased Demand in Trecora Resources (TREC)
-
bluebird bio (BLUE) Summer Sell-Off Creates Attractive Entry Point, Roth Capital Says
-
Roth Capital Reiterates Buy Rating on Intel (INTC) Ahead of 2Q15 Reports
-
Recent Dip in CECO Environmental (CECE) Creates Buying Opportunity - Roth Capital
-
Eco-stim Energy Solutions (ESES) Prices 5.5M Common Stock Offering at $4.75/Share
-
Eco-Stim Energy Solutions Announces Pricing of Public Offering of Common Stock
-
Eco-Stim Energy Solutions Announces Pricing of Public Offering of Common Stock
-
Roth Capital Resumes AcelRx Pharmaceuticals (ACRX) at Buy
-
Final Results of First Administrative Review of 2012 Tariffs Rule Worse than Expected - Roth (YGE) (FSLR) (TSL)
-
Notable Analyst Rating Changes 7/9: (TRV) (MBLY) (JBHT) Upgraded; (SHAK) (REGN) (VR) Downgraded
-
Roth Capital Remains Sidelined as Stock in PTC Therapeutics (PTCT) is Down ~14% YTD
-
H.C. Wainwright & Co., LLC Announces the Hiring of Ed Arce as Senior Biotechnology Analyst
-
Roth Capital Cuts Price Target on Golden Minerals Company (AUMN) After Updating Precious Metals Forecast
-
Roth Capital Upgrades New Gold (NGD) to Buy
-
EnteroMedics Inc. Announces Closing of $16.0 Million Public Offering of Common Stock and Warrants
-
PlacementTracker Publishes First Half 2015 PIPE Market League Tables
-
Roth Capital Starts 8point3 Energy Partners LP (CAFD) at Buy
-
Unique Fabricating, Inc. Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option by Underwriters
-
Ballard Announces Close of U.S. Offering
-
EnteroMedics (ETRM) Prices 32M Common Stock, Warrants Unit Offering at 50c/Unit
-
EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants
-
Roth Capital Starts Biotie Therapies (BITI) at Buy
-
Pieris Pharmaceuticals Closes Public Offering of Common Stock
-
Roth Capital Remains Bullish on NeoGenomics (NEO) Ahead of 2Q15 Results
-
Roth Capital Says Recent Pullbacks on uniQure (QURE) Offers Attractive Entry points; Reiterates Buy
-
Roth Capital Positive on Biogen (BIIB), AGTC (ATGC) Collaboration; Reaffirms AGTC at 'Buy'
-
Iconix Investors: Lieff Cabraser Announces Class Action Litigation Against Iconix Brand Group, Inc. - ICON
-
Roth Capital Cuts Price Target on Franklin Covey (FC) Following EPS Miss
-
Roth Capital Starts Green Plains Partners LP (GPP) at Buy
-
Unique Fabricating (UFAB) Prices 2.35M Common Stock IPO at $9.50/Share
-
Roth Capital Reiterates Buy Following Palatin Technologies (PTN) 'Positive' AdCom for Sprout's Flibanserin

